Barinthus Biotherapeutics (STU:2AB) 6-Month Price Index: 0.91 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2AB Barinthus Biotherapeutics PLC STU:2AB
14 GF Score
Price €0.57
GF Value €0.94
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics 6-Month Price Index?

Barinthus Biotherapeutics STU:2AB +2.73% 14 6-Month Price Index is 0.91 as of Jul. 17, 2026. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.94. The stock has 1 warning sign investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-07-17), Barinthus Biotherapeutics's 6-Month Price Index is 0.91.

Barinthus Biotherapeutics  (STU:2AB) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Barinthus Biotherapeutics 6-Month Price Index Related Terms

STU:2AB vs VTGN, PSTV, PVCT: 6-Month Price Index Comparison

For the Biotechnology subindustry, Barinthus Biotherapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

STU:2AB
14GF Score
Barinthus Biotherapeutics PLC STU:2AB
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics  (STU:2AB) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.91 mean?
Barinthus Biotherapeutics (STU:2AB) has a 6-Month Price Index of 0.91 as of Jul. 17, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Barinthus Biotherapeutics and its competitors.
Is Barinthus Biotherapeutics' 6-Month Price Index too high?
Barinthus Biotherapeutics' current 6-Month Price Index is 0.91. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' 6-Month Price Index compare to VTGN and PSTV?
Barinthus Biotherapeutics' 6-Month Price Index of 0.91 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current 6-Month Price Index is 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current 6-Month Price Index of 0.91. The stock's GF Value™ is €0.94, compared to a current price of €0.57 — trading 39.9% below its estimated fair value. The current 6-Month Price Index is 0.91. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current 6-Month Price Index is 0.91 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.57 is trading 39.9% below its estimated GF Value™ of €0.94.

Key valuation signals for STU:2AB:

  • 6-Month Price Index: 0.91
  • GF Value™: €0.94 vs. price of €0.57 (39.9% below fair value)
  • GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score

Get the complete analysis for STU:2AB

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.57
Price
€0.94
GF Value